Incannex Healthcare shares fall 2.82% after-hours following positive Phase 2 clinical trial results for PSX-001.

Incannex Healthcare Inc. dropped 2.82% in after-hours trading, despite reporting positive results from its Phase 2 clinical trial of PSX-001 for Generalised Anxiety Disorder. The trial showed statistically significant and clinically meaningful improvements across all key endpoints, reinforcing PSX-001’s potential as a best-in-class therapy for patients with moderate to severe GAD.